Zimbabwe has rejected a substantial US health deal worth $367m (272 million pounds) spanning five years over the United States' request for sensitive information.
The decision was revealed after a government memo from December was leaked, indicating that Head of State Emmerson Mnangagwa deemed the deal was "skewed".
A government spokesman has since explained that the United States was seeking health data for research and commercial gain while refused to guarantee the resulting advantages from future vaccines.
"We will now turn to the difficult and regrettable task of ending our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had provided over $1.9bn in health funding to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has called for continued negotiations to reach a agreement agreeable to both sides so the nation's critical HIV treatment initiative can be sustained.
Wider Background
Zimbabwe's decision follows a comparable situation in neighbouring Kenya, where a high court suspended a similar deal with the US following concerns were raised about the security of Kenyans' health data.
After returning to office last year, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
USAID had managed aid for the American government, but Trump stated its expenditure was "wasteful" and his government was pursuing direct bilateral deals to enhance transparency and responsibility.
As per reports, 16 nations in Africa have to date signed these new agreements, constituting more than $18.3bn in new funding.
Specifics of the Declined Agreement
The money for Zimbabwe was intended to funded "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this cooperation could have provided immense benefits for the people of Zimbabwe, particularly the 1.2 million currently on antiretroviral therapy via US-supported programmes," Tremont commented.
However, official spokesman Nick Mangwana said the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to provide its genetic material and health information over an extended period, without any equivalent guarantee of access to any scientific breakthroughs – such as new medicines or tests – that could be developed from that shared data," his statement read.
"Put simply, our nation would supply the raw materials for medical research with no assurance that the final treatments would be available to our citizens if a future pandemic arise."
Sovereignty and Global Health
Mangwana further noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral deals were disrupting frameworks previously set up through the global health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing framework designed to manage potential global health emergencies.
"This framework is designed to ensure that when a country contributes its information, the benefits – such as medicines and cures – are distributed fairly, not commercialised solely by those with the resources to develop them."
These objections over the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We encourage continued dialogue with our American counterparts on how subsequent co-operation could be arranged in a way that honours the independence and interests of both nations."
Medical Community Response
A leading public health body stated it acknowledged the government's concerns, but suggested that talks should continue since a large portion of the country's Aids initiatives depended on international support.
"If technical issues arise, such as those relating to information security or implementation frameworks, these can frequently be addressed via technical clarification and negotiated safeguards," the group added.
This impasse emphasises the ongoing challenges between accepting crucial foreign assistance and protecting a country's data in an increasingly data-driven world.